Eric Hunt / Wikimedia Commons
Why It Matters
As neighboring states continue to expand legal marijuana access and Idaho lawmakers keep cannabis policy on voters’ radar, the national conversation over high-potency cannabis products is intensifying. The health consequences associated with today’s far more potent marijuana supply are prompting legislative action across the country — and raising questions about how much regulation is too little, too late.
Idaho remains one of the few states with a full ban on recreational and medical marijuana, but the debate over ballot language for a marijuana amendment means Idahoans could eventually face the same policy choices now dividing state legislatures nationwide.
What Happened
Potency in commercially sold cannabis products has climbed dramatically over recent decades. Where marijuana flower once typically tested in the single digits for THC — the psychoactive compound — many products sold in legal markets today register between 15 and 20 percent. Cannabis concentrates can exceed 80 percent THC, a level virtually unrecognizable compared to earlier forms of the drug.
That shift is driving personal tragedies like the one Amy Wadsworth has lived through. Her son began using cannabis as a teenager, initially to manage social anxiety and sleep problems. He later developed psychotic episodes and severe cannabis use disorder and, now 25 years old, has cycled through hospitals and treatment programs for years.
Stories like Wadsworth’s are fueling legislative pushback in multiple states. Lawmakers in California, Georgia, Mississippi, Oklahoma, Oregon, and South Dakota have introduced measures this year aimed at capping THC potency levels. The efforts have met uneven success.
By the Numbers
- 15% of Americans aged 12 and older reported using marijuana in the past month in 2024.
- 3 in 10 cannabis users develop cannabis use disorder, according to public health data.
- 15–20% THC is now typical for many legally available cannabis products; some concentrates top 80%.
- 35% THC cap on flower was reinstated by Connecticut lawmakers weeks after they had voted to remove it.
- 5% was Georgia’s previous THC potency cap before Gov. Brian Kemp signed legislation eliminating it, effective July 1.
A Patchwork of State Responses
State-level action has been anything but uniform. Connecticut’s legislature reinstated a 35 percent cap on flower after briefly scrapping it, while simultaneously eliminating a 70 percent cap on concentrates and loosening restrictions on THC-infused beverages. Georgia moved in the opposite direction: Gov. Kemp signed a law removing the state’s existing 5 percent medical cannabis potency cap, adding a 12,000-milligram possession limit for registered patients and allowing those over 21 to vaporize medical marijuana.
Washington state has seen some of the most persistent legislative attempts to address potency concerns. State Rep. Lauren Davis has introduced at least five separate bills since 2020 targeting THC levels or requiring product safeguards. A 2024 measure succeeded in requiring retailers to warn customers about the documented connection between high-potency THC and psychotic disorders. However, Washington still does not cap THC in flower or concentrates, limiting caps to edibles and beverages. Davis has been blunt about industry opposition, saying the cannabis lobby has worked aggressively to defeat every reform effort she has pursued in this space.
Medical professionals are adding their voices to the debate. Dr. Alta DeRoo, chief medical officer of the Hazelden Betty Ford Foundation, argued that the federal reclassification of cannabis from Schedule I to Schedule III does not address the public health risks surrounding high-potency products. “Moving cannabis from Schedule I to Schedule III doesn’t help me save lives by decreasing the perception of that risk,” she said.
Zoom Out
The broader policy tension reflects a collision between rapidly expanding commercial cannabis markets and growing clinical evidence linking heavy, high-potency use to psychosis and addiction. Public health researchers have long noted that cannabis use disorder is far more prevalent than many casual users assume, with roughly three in ten regular consumers meeting diagnostic criteria.
For Idaho, where marijuana legalization remains a live political question, the experiences of states that legalized early offer a cautionary backdrop. The health consequences now prompting regulatory reversals elsewhere could inform how Idaho policymakers and voters approach any future cannabis measures.
What’s Next
State legislative sessions across the country will continue to wrestle with potency cap proposals, and outcomes are expected to vary sharply by state. Georgia’s revised medical cannabis rules take effect July 1. Advocacy groups on both sides of the issue are expected to remain active in lobbying efforts, while public health agencies push for clearer warning requirements and product standards regardless of whether hard potency limits advance.
About the Author
